This guidance describes FDA’s enforcement policy regarding certain firm-initiated communications of scientific information on unapproved use(s) of the firm’s approved/cleared medical products to health care providers (HCPs) engaged in prescribing or administering medical products to individual patients. The guidance describes the characteristics of the specific source publications contained in firm-initiated communications that fall within the enforcement policy outlined in this guidance.